<DOC>
	<DOC>NCT00002005</DOC>
	<brief_summary>To determine the safety profile and maximum tolerated dose (MTD) of recombinant soluble human CD4 (rCD4) therapy in patients with AIDS or AIDS related complex (ARC). To obtain a preliminary indication of the antiviral effects of rCD4 in patients with AIDS and ARC. To measure steady state serum levels of rCD4 following continuous infusion therapy.</brief_summary>
	<brief_title>A Phase I Study of Recombinant CD4(rCD4) in Patients With AIDS and AIDS-Related Complex</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>AIDS-Related Complex</mesh_term>
	<criteria>Inclusion Criteria Patients must have: HIV1 seropositivity. Diagnosis of AIDS or AIDS related complex (ARC). Failure to tolerate or respond to zidovudine (AZT) or decided to decline AZT therapy. The ability to sign a written informed consent form prior to treatment. A willingness to abstain from all other experimental therapy for HIV infection during the entire study period. A life expectancy of at least 3 months. Exclusion Criteria Coexisting Condition: Patients with the following conditions or symptoms are excluded: Serious active opportunistic infections. Malignancies other than Kaposi's sarcoma. Concurrent Medication: Excluded: Zidovudine (AZT). Corticosteroids. Nonsteroidal antiinflammatory agents (NSAI). Other experimental therapy. Patients with the following are excluded: Serious active opportunistic infections. Malignancies other than Kaposi's sarcoma. Prior Medication: Excluded within 3 weeks of study entry: Zidovudine (AZT). Chemotherapy. Immunomodulators. Other experimental therapy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 1990</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antigens, CD4</keyword>
	<keyword>AIDS-Related Complex</keyword>
</DOC>